Health Care • Biotechnology: Pharmaceutical Preparations
$3.04 ▲ +0.28
(+10.15%)
MKT CAP: $247.0M • VOL: 3.11M
52W L $1 52W H $5
ROARABLE / RQD
D • 49/100
PIOTROSKI
1 / 9
ELDN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | -$43.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$45.6M | -$36.2M | -$116.5M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$62.3M | -$47.3M | -$39.5M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$62.3M | -$47.3M | -$39.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | $22.8M | $20.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $81.1M | $62.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ELDN.